At least three households in Barry identified as having contracted the liver infection Health authorities have asked parents and carers to be “vigilant with their children’s hand-washing” after a hepatitis A outbreak in Barry, south Wales. At least three households in the seaside town have been identified as having contracted the same liver infection, amid worries it is spreading locally, Public H...
At least three households in Barry identified as having contracted the liver infection Health authorities have asked parents and carers to be “vigilant with their children’s hand-washing” after a hepatitis A outbreak in Barry, south Wales. At least three households in the seaside town have been identified as having contracted the same liver infection, amid worries it is spreading locally, Public Health Wales said. Continue reading...
Brian Keith Larabee, senior vice president and general manager of Elastomeric Material Solutions at Rogers Corporation (NYSE:ROG) , reported the sale of 830 shares of common stock for a transaction value of ~$113,000 on May 1, according to a SEC Form 4 filing . Transaction value based on SEC Form 4 reported price ($135.91); post-transaction value based on latest available market close price ($134....
Brian Keith Larabee, senior vice president and general manager of Elastomeric Material Solutions at Rogers Corporation (NYSE:ROG) , reported the sale of 830 shares of common stock for a transaction value of ~$113,000 on May 1, according to a SEC Form 4 filing . Transaction value based on SEC Form 4 reported price ($135.91); post-transaction value based on latest available market close price ($134.44 as of May 1, 2026). 1-year price change calculated using May 1, 2026, as the reference date. Continue reading
Xeris Pharmaceuticals press release ( XERS ): Q1 GAAP EPS of $0.01 beats by $0.02 . Revenue of $82M (+36.4% Y/Y) beats by $2.01M . Selling, general and administrative (SG&A) expenses increased $9.1 million or 21% in the first quarter of 2026 compared to the same period last year. This increase mainly reflects higher personnel related expense to support the commercial enterprise, including the Reco...
Xeris Pharmaceuticals press release ( XERS ): Q1 GAAP EPS of $0.01 beats by $0.02 . Revenue of $82M (+36.4% Y/Y) beats by $2.01M . Selling, general and administrative (SG&A) expenses increased $9.1 million or 21% in the first quarter of 2026 compared to the same period last year. This increase mainly reflects higher personnel related expense to support the commercial enterprise, including the Recorlev expansion. Net income for the first quarter was $2.2 million, compared to a net loss of $9.2 million in the same period last year. Adjusted EBITDA1 for the first quarter was $15.1 million, an improvement of $10.7 million compared to the same period last year. Total Shares Outstanding were 172,642,055 at April 30, 2026. More on Xeris Pharmaceuticals Xeris Biopharma Holdings, Inc. (XERS) Presents at Barclays 28th Annual Global Healthcare Conference Transcript Xeris Biopharma: Undervalued Given The Potential Of Its Drug Portfolio Xeris Biopharma Holdings, Inc. (XERS) Q4 2025 Earnings Call Transcript Xeris Pharmaceuticals Q1 2026 Earnings Preview Xeris rises on 2026 revenue guidance, Q4 top-line beat
Zoetis press release ( ZTS ): Q1 Non-GAAP EPS of $1.53 misses by $0.09. Revenue of $2.3B (+4.5% Y/Y) in-line. Revenue of $2.3 Billion, Growing 3%, and Net Income of $601 Million, or $1.42 per Diluted Share, Flat and Increasing 6%, Respectively, on a Reported Basis Adjusted Net Income of $646 Million, or Adjusted Diluted EPS of $1.53 Flat Organic Operational Growth in Revenue and 1% Organic Operati...
Zoetis press release ( ZTS ): Q1 Non-GAAP EPS of $1.53 misses by $0.09. Revenue of $2.3B (+4.5% Y/Y) in-line. Revenue of $2.3 Billion, Growing 3%, and Net Income of $601 Million, or $1.42 per Diluted Share, Flat and Increasing 6%, Respectively, on a Reported Basis Adjusted Net Income of $646 Million, or Adjusted Diluted EPS of $1.53 Flat Organic Operational Growth in Revenue and 1% Organic Operational Growth in Adjusted Net Income Revises Full Year 2026 Revenue Guidance to $9.680 - $9.960 Billion (vs. consensus of $9.89B) with Organic Operational Revenue Growth of 2% to 5% Revises Full Year 2026 Guidance for Organic Operational Growth in Adjusted Net Income to 2% to 6% Revises Guidance for Diluted EPS on an Adjusted Basis to $6.85 to $7.00 (vs. consensus of $7.03) More on Zoetis IDEXX Laboratories Vs. Zoetis: A Pre-Earnings Comparison Zoetis: Deep Value Persists Zoetis: Still Not Cheap Near 5-Year Lows Zoetis Q1 2026 Earnings Preview Zoetis outlines 3%–5% revenue growth target for 2026 amid competitive pressures and evolving pet care landscape
NORTH BETHESDA, Md., May 07, 2026 (GLOBE NEWSWIRE) -- Xometry, Inc. (NASDAQ: XMTR), the global AI-native marketplace connecting buyers and suppliers of custom manufacturing, today announced its financial results for the first quarter ended March 31, 2026.
NORTH BETHESDA, Md., May 07, 2026 (GLOBE NEWSWIRE) -- Xometry, Inc. (NASDAQ: XMTR), the global AI-native marketplace connecting buyers and suppliers of custom manufacturing, today announced its financial results for the first quarter ended March 31, 2026.
Cloud subscriptions revenue increased 25% year-over-year to $124.5 million, while cash flow provided by operations totaled $48.8 million Cloud subscriptions revenue increased 25% year-over-year to $124.5 million, while cash flow provided by operations totaled $48.8 million
Cloud subscriptions revenue increased 25% year-over-year to $124.5 million, while cash flow provided by operations totaled $48.8 million Cloud subscriptions revenue increased 25% year-over-year to $124.5 million, while cash flow provided by operations totaled $48.8 million
Datadog press release ( DDOG ): Q1 Non-GAAP EPS of $0.60 beats by $0.09 . Revenue of $1.01B (+32.5% Y/Y) beats by $50.06M . Non-GAAP operating income was $223 million; non-GAAP operating margin was 22%. Operating cash flow was $335 million, with free cash flow of $289 million. Cash, cash equivalents, and marketable securities were $4.8 billion as of March 31, 2026. First Quarter & Recent Business ...
Datadog press release ( DDOG ): Q1 Non-GAAP EPS of $0.60 beats by $0.09 . Revenue of $1.01B (+32.5% Y/Y) beats by $50.06M . Non-GAAP operating income was $223 million; non-GAAP operating margin was 22%. Operating cash flow was $335 million, with free cash flow of $289 million. Cash, cash equivalents, and marketable securities were $4.8 billion as of March 31, 2026. First Quarter & Recent Business Highlights: As of March 31, 2026, we had about 4,550 customers with ARR of $100,000 or more, an increase of 21% from about 3,770 as of March 31, 2025. Second Quarter and Full Year 2026 Outlook: Based on information as of today, May 7, 2026, Datadog is providing the following guidance: Second Quarter 2026 Outlook: Revenue between $1.07 billion and $1.08 billion vs. $994.47M consensus. Non-GAAP operating income between $225 million and $235 million. Non-GAAP net income per share between $0.57 and $0.59 vs. $0.50 consensus , assuming approximately 369 million weighted average diluted shares outstanding. Full Year 2026 Outlook: Revenue between $4.30 billion and $4.34 billion vs. $4.12B consensus (prior $4.06 billion and $4.10 billion). Non-GAAP operating income between $940 million and $980 million. Non-GAAP net income per share between $2.36 and $2.44 vs. $2.18 consensus (prior $2.08 and $2.16) , assuming approximately 372 million weighted average diluted shares outstanding. More on Datadog Datadog: AI Complexity Turning It Into A Must-Have Platform Datadog: Essential Infrastructure For Modern Technology Stacks Datadog Is A Buy: Why The SaaSpocalypse Doesn't Apply Here Datadog secures FedRAMP High certification for government cloud platform Datadog Q1 2026 Earnings Preview
The majority shareholder of Shenzhen-listed Wuliangye Yibin (Wuliangye) – China’s iconic premium baijiu producer – plans to increase its equity stake in the listed unit by purchasing between 3 billion yuan (US$441 million) and 5 billion yuan worth of shares over the next six months, in a move aimed at bolstering investor confidence after the stock slid to a six-year low. Analysts said the stake in...
The majority shareholder of Shenzhen-listed Wuliangye Yibin (Wuliangye) – China’s iconic premium baijiu producer – plans to increase its equity stake in the listed unit by purchasing between 3 billion yuan (US$441 million) and 5 billion yuan worth of shares over the next six months, in a move aimed at bolstering investor confidence after the stock slid to a six-year low. Analysts said the stake increase followed a prolonged downturn in China’s baijiu sector and growing unease among investors...
N-able press release ( NABL ): Q1 Non-GAAP EPS of $0.09 in-line. Revenue of $133.7M (+13.1% Y/Y) beats by $2.08M . As of March 31, 2026, total cash and cash equivalents were $117.8M, and total debt, net of debt issuance costs, was $393.1M. More on N-able N-able, Inc. (NABL) Q4 2025 Earnings Call Transcript Google Cloud partners with Thoma Bravo to advance AI adoption by enterprises N-able targets ...
N-able press release ( NABL ): Q1 Non-GAAP EPS of $0.09 in-line. Revenue of $133.7M (+13.1% Y/Y) beats by $2.08M . As of March 31, 2026, total cash and cash equivalents were $117.8M, and total debt, net of debt issuance costs, was $393.1M. More on N-able N-able, Inc. (NABL) Q4 2025 Earnings Call Transcript Google Cloud partners with Thoma Bravo to advance AI adoption by enterprises N-able targets $581M to $586M ARR in 2026 as AI-driven cybersecurity momentum builds Seeking Alpha’s Quant Rating on N-able Historical earnings data for N-able
Unity Software Inc press release ( U ): Q1 Non-GAAP EPS of $0.23 misses by $0.01 . Revenue of $508.23M (+16.8% Y/Y) beats by $3.22M . Create Solutions revenue was $157 million, compared to $150 million in the first quarter 2025. Grow Solutions revenue was $352 million, compared to $285 million in the first quarter 2025. Q2 2026 Guidance2 Total Revenue of $505 million to $515 million. Strategic Rev...
Unity Software Inc press release ( U ): Q1 Non-GAAP EPS of $0.23 misses by $0.01 . Revenue of $508.23M (+16.8% Y/Y) beats by $3.22M . Create Solutions revenue was $157 million, compared to $150 million in the first quarter 2025. Grow Solutions revenue was $352 million, compared to $285 million in the first quarter 2025. Q2 2026 Guidance2 Total Revenue of $505 million to $515 million. Strategic Revenue of $455 million to $465 million, up 29% - 32% year-over-year Strategic Grow Revenue of $302 million to $306 million, up 50% - 52% year-over-year Strategic Create Revenue of $154 million to $158 million up 11% - 14% year-over-year, when excluding the impact of a $12 million one-time revenue item in the second quarter of 2025. Adjusted EBITDA of $130 million to $135 million, up 44% - 49% year-over-year Shares +2.3% PM. More on Unity Software Inc Unity: Too Uncertain To Trust The Turnaround Unity: Upgrade To Strong Buy On Excellent Preliminary Q1 Results Unity: High SBC And A Looming AI Threat, Sell Unity preview: videogame engine maker faces growth test amid rising competition Wedbush reiterates Outperform ratings on AppLovin and Unity ahead of earnings reports
Iran is reviewing the Trump administration's latest proposal to end the war. And, Secretary of State Marco Rubio is meeting Pope Leo XIV amid President Trump's harsh criticism of him. (Image credit: Andrew Medichini)
Iran is reviewing the Trump administration's latest proposal to end the war. And, Secretary of State Marco Rubio is meeting Pope Leo XIV amid President Trump's harsh criticism of him. (Image credit: Andrew Medichini)
McDonald's press release ( MCD ): Q1 Non-GAAP EPS of $2.83 beats by $0.09 . Revenue of $6.52B (+9.4% Y/Y) beats by $50M . Global comparable sales increased 3.8% for the quarter, with consistently solid comparable sales growth across all segments U.S. increased 3.9% International Operated Markets increased 3.9% International Developmental Licensed Markets increased 3.4% Global Systemwide sales* inc...
McDonald's press release ( MCD ): Q1 Non-GAAP EPS of $2.83 beats by $0.09 . Revenue of $6.52B (+9.4% Y/Y) beats by $50M . Global comparable sales increased 3.8% for the quarter, with consistently solid comparable sales growth across all segments U.S. increased 3.9% International Operated Markets increased 3.9% International Developmental Licensed Markets increased 3.4% Global Systemwide sales* increased 11% (6% in constant currencies) to over $34 billion for the quarter Across 70 loyalty markets, Systemwide sales to loyalty members were over $38 billion for the trailing twelve-month period and over $9 billion for the quarter Shares +1.5% PM. More on McDonald's McDonald's: Value Strategy Holds, But Not A Q1 Catalyst McDonald's: Fundamentally Solid With Rewarding Dividends But Almost Fully Valued McDonald's: On Track To 50,000 Stores And Dividend King Status, But Risks Are Mounting McDonald’s earnings loom as traders bet big on loyalty and supply chain mentions McDonald's Q1 earnings on deck: What to expect
Knight Therapeutics press release ( KHTRF ): Q1 Non-GAAP EPS of $0.13. Revenue of $148.4M. More on Knight Therapeutics Inc. Knight Therapeutics Inc. (GUD:CA) Shareholder/Analyst Call Prepared Remarks Transcript Knight Therapeutics Inc. (GUD:CA) Q4 2025 Earnings Call Transcript Knight Therapeutics announces approval of additional indication for MINJUVI in Brazil Historical earnings data for Knight ...
Knight Therapeutics press release ( KHTRF ): Q1 Non-GAAP EPS of $0.13. Revenue of $148.4M. More on Knight Therapeutics Inc. Knight Therapeutics Inc. (GUD:CA) Shareholder/Analyst Call Prepared Remarks Transcript Knight Therapeutics Inc. (GUD:CA) Q4 2025 Earnings Call Transcript Knight Therapeutics announces approval of additional indication for MINJUVI in Brazil Historical earnings data for Knight Therapeutics Inc. Financial information for Knight Therapeutics Inc.
SEATTLE, May 07, 2026--Amazon Pharmacy (NASDAQ: AMZN), a full-service digital pharmacy that delivers medications directly to customers' homes, is expanding access to Novo Nordisk's Ozempic® pill, the only FDA-approved oral GLP-1 medication to treat type 2 diabetes. Amazon Pharmacy will offer Same-Day prescription delivery and pickup within minutes through in-office kiosk locations soon, addressing...
SEATTLE, May 07, 2026--Amazon Pharmacy (NASDAQ: AMZN), a full-service digital pharmacy that delivers medications directly to customers' homes, is expanding access to Novo Nordisk's Ozempic® pill, the only FDA-approved oral GLP-1 medication to treat type 2 diabetes. Amazon Pharmacy will offer Same-Day prescription delivery and pickup within minutes through in-office kiosk locations soon, addressing a critical access gap for the more than 36 million Americans living with type 2 diabetes.
Klabin press release ( KLBAY ): Q1 net loss of -R$497M (vs. R$446M in Q1/2025). Net revenue of R$4,946M (+2% Y/Y). More on Klabin Klabin S.A. (KLBAY) Q4 2025 Earnings Call Transcript Klabin S.A. 2025 Q4 - Results - Earnings Call Presentation Seeking Alpha’s Quant Rating on Klabin Historical earnings data for Klabin Financial information for Klabin
Klabin press release ( KLBAY ): Q1 net loss of -R$497M (vs. R$446M in Q1/2025). Net revenue of R$4,946M (+2% Y/Y). More on Klabin Klabin S.A. (KLBAY) Q4 2025 Earnings Call Transcript Klabin S.A. 2025 Q4 - Results - Earnings Call Presentation Seeking Alpha’s Quant Rating on Klabin Historical earnings data for Klabin Financial information for Klabin